)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Diamyd Medical
Diamyd Medical (DMYD) investor relations material
Diamyd Medical Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary7 Oct, 2026
Executive summary
FY 2025/26 net sales were MSEK 0.5 and net loss was MSEK 255.6; the year included the early termination of DIAGNODE-3 and a strategic refocus on retogatein.
Management expects the current cash position to fund operations for more than two years under the approved budget, following cost reductions and study-closure expenses.
Financial highlights
Net sales were MSEK 0.5 vs. 0.1 YoY; Q4 sales were MSEK 0.1 vs. 0.0.
Net loss was MSEK 255.6 vs. 169.8; Q4 net loss was MSEK 16.8 vs. 44.9.
Operating loss was MSEK 262.3 vs. 183.2; external R&D costs were MSEK 180.1 vs. 119.5.
Operating cash flow was MSEK -195.3 vs. -169.7; Q4 operating cash flow was MSEK -40.4 vs. -35.9.
Cash and short-term investments were MSEK 305.4 at Aug. 31, 2026, vs. MSEK 277.2 a year earlier.
Outlook and guidance
Approved-budget cash runway is expected to exceed two years.
Priorities include developing retogatein for early-stage T1D, expanding Umeå manufacturing projects, broadening partner discussions, and making selected limited investments.
The next retogatein drug-substance batch is scheduled for production before year-end.
Clinical investigators are being engaged on trial designs for people matching retogatein’s genetically defined responder profile; pharmaceutical-company discussions continue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Diamyd Medical
- Precision therapies and regulatory momentum signal major advances in type 1 diabetes treatment.DMYD
Status Update - Phase III precision therapy for Type 1 diabetes nears early readout, targeting genetic subgroups.DMYDInvesting in Life Science 2025
- DIAGNODE-3 trial discontinued, leadership reshuffled, and focus shifts to strategic cash deployment.DMYDQ3 25/26
- Retogatein targets HLA DR3-DQ2 positive type 1 diabetes with strong clinical and regulatory progress.DMYDCompany presentation
- Phase III interim analysis showed futility and no efficacy, prompting urgent review and investigation.DMYDStudy result
- Phase III trial fully enrolled, interim results and up to $160M in funding secured.DMYDQ2 25/26
- Phase 3 trial of retogatein advances toward early efficacy readout and potential accelerated approval.DMYDQ1 25/26
- Phase III trial targets HLA-selected type 1 diabetes patients, with interim results due soon.DMYDLilla Lördag
- Pivotal Phase 3 trial advances, financials strengthened, and new patents support future growth.DMYDQ4 24/25
Next Diamyd Medical earnings date
Q1 26/2726 Jan, 2027
Diamyd Medical
Next Diamyd Medical earnings date
Q1 26/2726 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Diamyd Medical AB is a biotechnology company headquartered in Stockholm, Sweden, specializing in the development of immune modifying therapies for diabetes. The company is actively engaged in the pharmaceutical development field, focusing on two innovative disease-modifying drugs: Diamyd, an antigen-specific immunotherapy, and Remygen, an oral regenerative and immunomodulatory therapeutic. These drugs are undergoing clinical trials and are designed to address the underlying causes of diabetes, including dysfunction and loss of the pancreas's insulin-producing cells. Diamyd Medical operates a manufacturing facility in Umeå and leverages a global network of clinics, researchers, and production units for its development efforts. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.